Guardant Health to Acquire Cancer Detection Startup MetaSight
Cancer detection firm Guardant Health has acquired startup MetaSight in a deal worth up to $150 million. The acquisition expands Guardant's capabilities in early cancer detection, a field that heavily relies on bioinformatics and translational research.
- The acquisition payment structure includes $59 million in upfront cash, with an additional $90 million contingent on future commercial and regulatory milestones. - MetaSight, an Israeli startup, specializes in "liquid biopsies," which are blood tests for the early detection of cancer and other diseases. Their technology will establish Guardant Health's first research and development center outside of the U.S. - While Guardant Health primarily focuses on analyzing circulating tumor DNA (ctDNA), MetaSight uses a multi-omics approach, analyzing metabolites, lipids, and proteins with mass spectrometry to find disease signals. - This deal showcases the role of translational research, which aims to "translate" discoveries from basic science into tangible clinical tools, like developing a new diagnostic test based on newly identified cancer biomarkers. - The technologies at both companies heavily rely on bioinformatics, a field that combines biology, computer science, and statistics to analyze massive datasets from patient samples, identifying patterns that can indicate the presence of cancer. - MetaSight was founded by Professor Tomer Shlomi from the Technion – Israel Institute of Technology, highlighting a career path where academic research leads directly to the creation of a startup company. - Guardant Health's existing product line includes tests for different stages of cancer, from the FDA-approved "Shield" test for colorectal cancer screening in average-risk individuals to "Guardant Reveal" for monitoring disease recurrence after surgery.
